CG Invites Co

CG Invites Co EPS

The Earnings per Share (EPS) of CG Invites Co (083790.KQ) as of Oct 24, 2026 is -98.08 KRW. In the previous year, Earnings per Share (EPS) was -1,435.74 KRW — a change of -93.17% (higher).

EPS

-98.08KRW

YoY

-93.17%

Last updated:

Earnings per Share (EPS) of CG Invites Co is 2025 -98.08 KRW. Earnings per Share (EPS) of CG Invites Co was 2024 -1,435.74 KRW. It decreases by -93.17% higher compared to the previous year.

The CG Invites Co EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2018
192.41 KRW
Jan 1, 2019
-1,046.93 KRW
Jan 1, 2020
-274.03 KRW
Jan 1, 2021
-442.91 KRW
Jan 1, 2022
-664.86 KRW
Jan 1, 2023
-1,362.75 KRW
Jan 1, 2024
-1,435.74 KRW
Jan 1, 2025
-98.08 KRW
The CG Invites Co EPS history
YEAREPSYoY
-98.08KRW-93.17%
-1,435.74KRW+5.36%
-1,362.75KRW+104.97%
-664.86KRW+50.11%
-442.91KRW+61.63%
-274.03KRW-73.83%
-1,046.93KRW-644.12%
192.41KRW-180.55%
-238.87KRW+293.47%
-60.71KRW-55.06%
-135.09KRW-59.35%
-332.33KRW+24.30%
-267.37KRW-331.11%
115.69KRW-143.68%
-264.86KRW+79.48%
-147.57KRW+15.29%
-128.00KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CG Invites Co Stock analysis

What does CG Invites Co do? CrystalGenomics, Inc. generates revenue through its Finished Pharmaceuticals Manufacturing segment, which produces and sells finished pharmaceuticals. The Pharmaceutical R&D Division provides clinical trial analysis and technical services while also selling new drugs. The company also operates in the real estate leasing business under the segment structure. The Others segment manufactures and sells hot fats and other household items. Revenue streams are derived from pharmaceutical manufacturing, R&D services, real estate leasing, and household product sales. The primary buyers for finished pharmaceuticals include healthcare providers and distributors. Clinical trial analysis and new drug sales target pharmaceutical companies and research institutions. Real estate leasing serves commercial tenants, while hot fats and household items are sold to retail consumers. The company's segments collectively serve diverse markets across healthcare, real estate, and consumer goods. CrystalGenomics, Inc. focuses on therapeutic discovery and development, with its R&D Division driving innovation in new drug sales. The Finished Pharmaceuticals Manufacturing segment ensures steady supply of established products. Real estate leasing and household item sales provide additional revenue streams. The company's business model integrates pharmaceutical production, research, and non-pharmaceutical ventures. CG Invites Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CG Invites Co stock

Earnings per Share (EPS) of CG Invites Co is -98.08 KRW in 2025.

Earnings per Share (EPS) of CG Invites Co changed from -1,435.74 KRW to -98.08 KRW, representing a -93.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) CG Invites Co since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — CG Invites Co

All Key Metrics — CG Invites Co